Angiogenic factors for prediction of preeclampsia and intrauterine growth restriction onset in high-risk women: AngioPred study

References

• Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–137.
   PubMed Web of Science ®Google Scholar
• Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. J Am Med Assoc. 1991;266(2):237–241.
   PubMed Web of Science ®Google Scholar
• Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–649.
   PubMed Web of Science ®Google Scholar
• Schlembach D, Wallner W, Sengenberger R, et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2007;29(4):407–413.
   PubMed Web of Science ®Google Scholar
• Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol. 2007;109(1):168–180.
   PubMed Web of Science ®Google Scholar
• Espinoza J, Chaiworapongsa T, Romero R, et al. Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med. 2007;20:495–507.
   PubMed Web of Science ®Google Scholar
• Germain AM, Romanik MC, Guerra I, et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension. 2007;49(1):90–95.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005.
   PubMed Web of Science ®Google Scholar
• Stepan H, Krämer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab. 2007;92(7):2831–2834.
   PubMed Web of Science ®Google Scholar
• Kleinrouweler CE, Wiegerinck MMJ, Ris-Stalpers C, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG. 2012;119(7):778–787.
   PubMed Web of Science ®Google Scholar
• Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med. 2012;25(12):2651–2657.
   PubMed Web of Science ®Google Scholar
• Powers RW, Jeyabalan A, Clifton RG, et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One. 2010;5(10):e13263.
   PubMed Web of Science ®Google Scholar
• O’Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol. 2016;214(1):103.e1–103.e12.
   PubMed Web of Science ®Google Scholar
• Gallo DM, Wright D, Casanova C, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19–24 weeks’ gestation. Am J Obstet Gynecol. 2016;214(5):619.e1–619.e17.
   PubMed Web of Science ®Google Scholar
• Tsiakkas A, Saiid Y, Wright A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30–34 weeks’ gestation. Am J Obstet Gynecol. 2016;215(1):87.e1–87.e17.
   PubMed Web of Science ®Google Scholar
• Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97–104.
   PubMed Web of Science ®Google Scholar
• Mamelle N, Munoz F, Grandjean H. Fetal growth from the AUDIPOG study. I. Establishment of reference curves. J Gynecol Obstet Biol Reprod (Paris). 1996;25(1):61–70.
   PubMedGoogle Scholar
• Margolis DJ, Bilker W, Boston R, et al. Statistical characteristics of area under the receiver operating characteristic curve for a simple prognostic model using traditional and bootstrapped approaches. J Clin Epidemiol. 2002;55(5):518–524.
   PubMed Web of Science ®Google Scholar
• Moore Simas TA, Crawford SL, Bathgate S, et al. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. J Matern Fetal Neonatal Med. 2014;27(10):1038–1048.
   PubMed Web of Science ®Google Scholar
• Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007;197(3):244.e1–244.e8.
   Web of Science ®Google Scholar
• Salahuddin S, Lee Y, Vadnais M, et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 2007;197(1):28.e1–28.e6.
   Web of Science ®Google Scholar
• Teixeira PG, Reis ZSN, Andrade SP, et al. Presymptomatic prediction of preeclampsia with angiogenic factors, in high risk pregnant women. Hypertens Pregnancy. 2013;32(3):312–320.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Crawford SL, Bathgate S, et al. Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Am J Obstet Gynecol. 2013;209(1):53.e1–53.e9.
   Web of Science ®Google Scholar